O Shaughnessy Asset Management LLC Has $65.26 Million Stock Position in Pfizer Inc. $PFE

O Shaughnessy Asset Management LLC increased its position in Pfizer Inc. (NYSE:PFE) by 47.1% in the 4th quarter, Holdings Channel reports. The firm owned 2,621,063 shares of the biopharmaceutical company’s stock after buying an additional 838,851 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Pfizer were worth $65,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Horizon Financial Services LLC lifted its position in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the period. Godfrey Financial Associates Inc. bought a new position in Pfizer in the fourth quarter worth $26,000. YANKCOM Partnership bought a new position in Pfizer in the fourth quarter worth $28,000. HFM Investment Advisors LLC lifted its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Darwin Wealth Management LLC bought a new position in Pfizer in the second quarter worth $32,000. 68.36% of the stock is owned by institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Pfizer Stock Up 0.0%

Shares of NYSE PFE opened at $26.04 on Monday. The stock has a market cap of $148.43 billion, a PE ratio of 19.88 and a beta of 0.34. The business has a fifty day moving average of $26.62 and a two-hundred day moving average of $26.30. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

Several brokerages recently commented on PFE. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. UBS Group reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. CICC Research initiated coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. Finally, Barclays initiated coverage on Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.